Cargando…

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies

BACKGROUND: Linezolid is increasingly important for multidrug-resistant tuberculosis (MDR-TB) treatment. However, among children with MDR-TB, there are no linezolid pharmacokinetic data, and its adverse effects have not yet been prospectively described. We characterised the pharmacokinetics, safety,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia-Prats, Anthony J., Schaaf, H. Simon, Draper, Heather R., Garcia-Cremades, Maria, Winckler, Jana, Wiesner, Lubbe, Hesseling, Anneke C., Savic, Rada M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490911/ https://www.ncbi.nlm.nih.gov/pubmed/31039153 http://dx.doi.org/10.1371/journal.pmed.1002789

Ejemplares similares

Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
por: van der Laan, Louvina E., et al.
Publicado: (2021)

Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children
por: van der Laan, Louvina E, et al.
Publicado: (2023)

QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies
por: Ali, Ali Mohamed, et al.
Publicado: (2023)

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
por: Zhang, Haoyue, et al.
Publicado: (2023)

Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial
por: Garcia-Prats, Anthony J., et al.
Publicado: (2022)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

Tuberculosis Disease during Pregnancy and Treatment Outcomes in HIV-Infected and Uninfected Women at a Referral Hospital in Cape Town
por: Bekker, Adrie, et al.
Publicado: (2016)

Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study
por: Franck, Caroline, et al.
Publicado: (2014)

Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
por: Resendiz-Galvan, Juan Eduardo, et al.
Publicado: (2023)

Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study
por: Seddon, James A, et al.
Publicado: (2013)

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
por: Svensson, Elin M., et al.
Publicado: (2018)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021)

Practical and psychosocial challenges faced by caregivers influence the acceptability of multidrug-resistant tuberculosis preventive therapy for young children
por: Wademan, Dillon T., et al.
Publicado: (2022)

Tuberculosis: opportunities and challenges for the 90–90–90 targets in HIV-infected children
por: Rabie, Helena, et al.
Publicado: (2015)

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis
por: Bigelow, Kristina M, et al.
Publicado: (2020)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

Clinical Pharmacokinetics of Oral Sodium Selenite and Dosing Implications in the Treatment of Patients with Metastatic Cancer
por: Jayachandran, Priya, et al.
Publicado: (2021)

Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis
por: Yuan, Yuan, et al.
Publicado: (2022)

A Review of Population Pharmacokinetic Analyses of Linezolid
por: Bandín-Vilar, Enrique, et al.
Publicado: (2022)

Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)
por: Seddon, James A., et al.
Publicado: (2018)

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
por: Imperial, Marjorie Z, et al.
Publicado: (2021)

Population pharmacokinetics of ethambutol in African children: a pooled analysis
por: Tikiso, Tjokosela, et al.
Publicado: (2022)

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?
por: Grard, Soazic, et al.
Publicado: (2015)

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
por: Jaspard, Marie, et al.
Publicado: (2020)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model
por: Mao, Jun, et al.
Publicado: (2021)

Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis
por: Azimi, Taher, et al.
Publicado: (2022)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies
por: Garcia-Prats, Anthony J, et al.
Publicado: (2020)

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
por: Mockeliunas, Laurynas, et al.
Publicado: (2022)

Pediatric tuberculosis: clinical and epidemiological reflections from a highly endemic setting
por: Hesseling, Anneke
Publicado: (2010)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2021)

Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis
por: Li, Yuan, et al.
Publicado: (2019)

Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013–2018
por: McDowell, Ashley, et al.
Publicado: (2020)

Linezolid-induced black hairy tongue in a patient with multidrug-resistant tuberculosis: A case report
por: Lee, Jaemin, et al.
Publicado: (2021)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2023)

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients
por: Shao, Ge, et al.
Publicado: (2023)

Toward a conceptual framework of the acceptability of tuberculosis treatment in children using a theory generative approach
por: Wademan, Dillon T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ek08pllmv6pulavb47kup8mj16